NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Battle of the NASH Thrones Spring Investor Conference on Thursday, March 28, 2019 at the Park Hyatt Hotel in New York City.
ROTH’s Battle of the NASH Thrones Spring Investor Conference, taking place just one day after the release of EASL abstracts, will give investors the opportunity to interact with senior management of a select group of prominent public and private companies focused on Non-alcoholic Steatohepatitis (NASH), an indication slated to have an exciting year with several prominent Phase 3 data readouts in 2019. Yasmeen Rahimi, Ph.D., Managing Director, Senior Research Analyst, will also be moderating five panel discussions on hot NASH topics. First, on the heels of the release of EASL abstracts, we will have an “EASL Mystery Panel” based on scientific abstracts that will be released just one day before our NASH conference. Our “NASH Pricing Deconstructed” panel will feature several pricing experts to discuss how pricing and reimbursement in NASH will shape up, and our “Why MRI May Hold the Key to the Kingdom in Diagnosis and Drug Development” panel will discuss the importance and use of non-invasive imaging tools. Additionally, we will focus on specific mechanisms of action and clinical results in our “12 Months of Data: 2019 is the Year for FXR and PPAR Clinical Readouts” and “Integrins: New Adversaries for the NASH Throne” panels.
ROTH has built a leading Healthcare Investment Banking Group over the
last several years and has raised approximately $16+ billion in over 400
Healthcare transactions since 2010.
*Past Performance is not
indicative of future returns. (Source: ROTH Capital Partners |
03/20/2019)
The event is for institutional clients of ROTH and is by invitation only. For more information, please contact your ROTH sales representative at (949) 720-5700 or e-mail: pc@roth.com.
Agenda and Events:
7:00am - 8:00am | Morning Coffee & Registration
7:45am - 8:00am
| Introduction by Yasmeen Rahimi, Ph.D.
8:00am - 5:30pm | Panels
(Details Below)
9:00am - 4:00pm | 1-on-1 / Small Group Meetings (excluding
panel times)
12:00pm - 1:00pm | Working Lunch
12:00pm -
12:10pm | The NASH Patient Perspective by David Frank
Panels:
8:00am - 9:00am
12 Months of Data: 2019
Is the Year for FXR and PPAR Clinical Readouts
FXR contenders:
Intercept Pharmaceuticals, Enanta Pharmaceuticals, Metacrine
PPAR
contenders: CymaBay Therapeutics
12:00pm - 1:00pm
EASL Mystery Panel
As an exciting
lead-up to the EASL conference, contenders will be notified on March 27
of their participation in this panel upon the release of EASL abstracts
1:00pm - 2:00pm
Integrins: New Adversaries for the NASH
Throne?
Integrin contenders: Pliant Therapeutics
KOL: Scott
Friedman, M.D. and Dean Sheppard, M.D.
4:00pm - 4:45pm
Why MRI May Hold the Key to the Kingdom in
Diagnosis and Drug Development
CymaBay Therapeutics, Madrigal
Pharmaceuticals, Perspectum Diagnostics and American Liver Foundation
KOL:
Stephen Harrison, M.D. and Amon Asgharpour, M.D.
4:45pm - 5:30pm
NASH Pricing Deconstructed: Thoughts From
the Masters of Coin
Roger Green (RG&A Consulting), Peter Gilmore
(KPMG Strategy) and Brian E Harvey, M.D. Ph.D. (Global Liver Institute)
Venue:
Park Hyatt New York
153 W 57th St, New
York, NY 10019
Tel: 646.774.1234
Participating Companies
The following participating
companies are confirmed as of the date of this release:
| Company Name |
| 89-Bio, Inc. (Private) |
| Akero Therapeutics, Inc. (Private) |
|
Albireo Pharma, Inc. (ALBO)
American Liver Foundation (Private) |
| Conatus Pharmaceuticals, Inc. (CNAT) |
| ContraVir Pharmaceuticals, Inc. (CTRV) |
| CymaBay Therapeutics, Inc. (CBAY) |
| Enanta Pharmaceuticals, Inc. (ENTA) |
|
Galectin Therapeutics, Inc. (GALT)
Galmed Pharmaceuticals, Inc. (GLMD) |
|
Genkyotex S.A. (ENXTPA:GKTX)
Global Liver Institute (Private) |
| Intercept Pharmaceuticals, Inc. (ICPT) |
| Inventiva S.A. (ENXTPA:IVA) |
| Lipocine, Inc. (LPCN) |
| Madrigal Pharmaceuticals, Inc. (MDGL) |
| Metacrine, Inc (Private) |
| Mirum Pharmaceuticals, Inc. (Private) |
|
North Sea Therapeutics, Inc. (Private)
Organovo Holdings, Inc. (ONVO) |
| Pliant Therapeutics, Inc. (Private) |
| Perspectum Diagnostics Ltd. (Private) |
| Soleno Therapeutics, Inc. (SLNO) |
|
Stero Therapeutics, Inc. (Private)
Zafgen, Inc. (ZFGN) |
Event sponsors include Business Wire and Lowenstein Sandler.
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
